Financial Data and Key Metrics Changes - Total revenues for the quarter were CNY 297.3 million, down 60.6% year over year, primarily due to a decrease in the number of medical service providers subscribing to information services on the platform [16] - Net loss attributable to So Young was CNY 33.1 million, compared to a net loss of CNY 21.2 million during the same period last year [20] - Non-GAAP net loss attributable to So Young was CNY 31.5 million, compared to non-GAAP net income of CNY 4.1 million during the same period of 2024 [20] - Basic and diluted losses per ADS attributable to ordinary shareholders were CNY 0.32, compared to CNY 0.21 during the same period of 2024 [21] - Cash and cash equivalents totaled CNY 1.1 billion as of March 31, 2025, indicating a robust cash position [21] Business Line Data and Key Metrics Changes - Revenue from aesthetic treatment services reached CNY 98.8 million, a remarkable 551.4% year over year increase, primarily due to the expansion of the aesthetic center business [17] - Total verified paid visits exceeded 45,500, up 18.5% quarter on quarter and 874.3% year over year [8] - Total number of verified paid aesthetic treatments performed surpassed 92,900, up 14% quarter on quarter and 989.4% year over year [8] - Customer satisfaction remains high at 4.98 out of 5, reflecting the commitment to maintaining high service delivery standards [9] Market Data and Key Metrics Changes - The aesthetic center business is gradually becoming the main growth driver, with 23 centers opened in nine major cities, including Beijing and Shanghai [7] - 18 centers have achieved positive monthly operating cash flow, and 16 centers are profitable on a monthly basis as of March [7] Company Strategy and Development Direction - The company is pursuing a vertical integration strategy and expanding its network of aesthetic centers in key cities, focusing on high-quality, cost-effective, and standardized services [6] - The strategy is inspired by the Sam's Club retail model, emphasizing proprietary products, value-for-money pricing, and end-to-end supply chain management [13][22] - The company aims to build a differentiated nationwide light medical aesthetic chain with strong brand recognition [12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the aesthetic center business, emphasizing the importance of maintaining a robust cash position and careful management of capital expenditures [21][36] - The company expects aesthetic treatment services revenues for Q2 2025 to be between CNY 120 million and CNY 140 million, representing a 337.3% to 410.1% increase from the same period in 2024 [21][22] - Management views trade tensions as an opportunity to strengthen the domestic supply chain and support import replacement, with minimal direct impact on the aesthetic center business [45][46] Other Important Information - The company has allocated additional marketing resources and implemented sales incentives to boost revenue contribution from proprietary products, aiming to improve overall gross margins for aesthetic centers [11] - The number of institutions served with supply chain solutions for injectables grew to over 1,500, with shipments of elasticity reaching approximately 27,900 units in Q1, up roughly 14% year over year [11] Q&A Session Summary Question: How is So Young Clinic different from traditional medical institutions like Meilai and Istar? - The aesthetic center business operates on a fast casual model, offering focused services in smaller clinics with higher visit frequency, contrasting with traditional models that require larger spaces and generate higher per customer spend but with less frequency [26][27][28] Question: Will CapEx become a burden for the company as the clinic network grows? - The company emphasizes careful management of CapEx and plans to open around 30 new clinics per year, with a focus on profitability and the potential rollout of a franchise model to reduce CapEx pressure [36][37] Question: How does the Miracle Laser create more synergy with the company's core business? - The integration of Wuhan Medical Laser improves R&D capabilities and supports the growth model by supplying high-quality, cost-effective equipment to aesthetic centers, reducing reliance on imported devices [40][41] Question: How will ongoing trade tensions impact the company's business? - The direct impact is limited, with only a small portion of offerings relying on U.S. imports. The company sees this as an opportunity to enhance the domestic supply chain and pivot to alternative products if necessary [45][46] Question: Can management elaborate on future investment plans and cost reduction strategies? - The company remains focused on sustainable growth, optimizing service offerings, and enhancing efficiency at the clinic level while increasing investment in proprietary product lines to support margin expansion [50][52]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were CNY 297.3 million, down 60.6% year over year, primarily due to a decrease in the number of medical service providers subscribing to information services [14] - Net loss attributable to So Young was CNY 33.1 million, compared to a net loss of CNY 21.2 million in the same period last year [17] - Non-GAAP net loss attributable to So Young was CNY 31.5 million, compared to non-GAAP net income of CNY 4.1 million during the same period in 2024 [17] - Basic and diluted losses per ADS were CNY 0.32, compared to CNY 0.21 in the same period of 2024 [18] - Cash and cash equivalents totaled CNY 1.1 billion as of March 31, 2025, indicating a robust cash position [18] Business Line Data and Key Metrics Changes - Revenue from aesthetic treatment services reached CNY 98.8 million, a remarkable 551.4% year over year increase, primarily due to the expansion of the aesthetic center business [15] - Total verified paid visits exceeded 45,500, up 18.5% quarter on quarter and 874.3% year over year [7] - Total number of verified paid aesthetic treatments performed surpassed 92,900, up 14% quarter on quarter and 989.4% year over year [7] - Cost of aesthetic treatment services was CNY 80.3 million, up 547.6% year over year, primarily due to the expansion of the aesthetic center business [16] Market Data and Key Metrics Changes - The aesthetic center business is gradually becoming the main growth driver, with 18 centers achieving positive monthly operating cash flow and 16 centers being profitable on a monthly basis as of March [6] - The company aims to build a differentiated nationwide light medical aesthetic chain with strong brand recognition [10] Company Strategy and Development Direction - The company is pursuing a vertical integration strategy and expanding its network of aesthetic centers in major cities [5] - A franchise model is being planned to accelerate geographic reach and network density while reducing capital expenditure pressure [32] - The company aims to develop proprietary products and control the supply chain, inspired by the Sam's Club retail model [11][19] - The focus is on high-quality proprietary products and services at fair prices, aiming to become a leading player in the medical aesthetics industry [12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the aesthetic center business, emphasizing the importance of maintaining a sustainable financial model [32] - The company views trade tensions as an opportunity to strengthen its domestic supply chain and support import replacement [41] - The outlook for Q2 2025 expects aesthetic treatment services revenues to be between CNY 120 million and CNY 140 million, representing a 337.3% to 410.1% increase from the same period in 2024 [18][19] Other Important Information - The company has allocated additional marketing resources and implemented sales incentives to boost revenue contribution from proprietary products [9] - The number of institutions served with supply chain solutions for injectables grew to over 1,500 as of Q1 [9] Q&A Session Summary Question: How is So Young Clinic different from traditional medical institutions like Meilai and Istar? - The aesthetic center business uses a fast casual model, offering focused services with higher frequency and lower per customer spend compared to traditional models [23][24] Question: Will CapEx become a burden for the company as the clinic network grows? - The company emphasizes careful management of CapEx and plans to open around 30 new clinics per year while exploring a franchise model to reduce CapEx pressure [32][33] Question: How does the Miracle Laser create more synergy with the company's core business? - The integration of Wuhan Medical Laser improves R&D capabilities and supports the growth model by supplying high-quality, cost-effective equipment to aesthetic centers [35][36] Question: How will ongoing trade tensions impact the company's business? - The direct impact is limited, but the company sees it as an opportunity to strengthen its domestic supply chain and pivot to alternative products if necessary [41][43] Question: Can management elaborate on the company's future investment plan and cost reduction plan? - The company remains focused on sustainable growth, optimizing offerings, and increasing investment in proprietary product lines to support margin expansion [45][46]

Exhibit 99.1 So-Young Reports Unaudited First Quarter 2025 Financial Results BEIJING, China, May 16, 2025 — So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights First Quarter 2025 Operational Highlights This press release contains translations o ...

Core Viewpoint - So-Young International Inc. reported its first quarter 2025 financial results, highlighting a decrease in total revenues but significant growth in aesthetic treatment services, indicating a shift in business dynamics and ongoing strategic investments to support long-term growth [1][5][19]. Financial Highlights - Total revenues for Q1 2025 were RMB 297.3 million (US$ 41.0 million), a decrease of 6.6% from RMB 318.3 million in Q1 2024 [5][6]. - Net loss attributable to So-Young was RMB 33.1 million (US$ 4.6 million), compared to a net loss of RMB 21.2 million in the same period of 2024 [12][13]. - Non-GAAP net loss was RMB 31.5 million (US$ 4.3 million), a significant decline from a non-GAAP net income of RMB 4.1 million in Q1 2024 [13][6]. - The aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was RMB 303.2 million, down from RMB 367.1 million in Q1 2024 [6]. Operational Highlights - The number of verified paid visits for the quarter reached over 45,500, compared to approximately 4,600 in the same period of 2024 [6]. - The number of verified paid aesthetic treatments performed surpassed 92,900, compared to approximately 8,500 in Q1 2024 [6]. - As of March 31, 2025, So-Young operated 23 aesthetic centers across nine major cities, with 18 centers achieving positive monthly operating cash flow [6]. Revenue Breakdown - Revenue from aesthetic treatment services was RMB 98.8 million (US$ 13.6 million), an increase of 551.4% from RMB 15.2 million in Q1 2024 [16]. - Revenue from information, reservation services, and other sources was RMB 142.9 million (US$ 19.7 million), a decrease of 34.1% from RMB 216.6 million in Q1 2024 [5][16]. - Sales of medical products and maintenance services were RMB 55.6 million (US$ 7.7 million), a decrease of 35.7% from RMB 86.5 million in Q1 2024 [16]. Cost and Expenses - Cost of revenues was RMB 151.4 million (US$ 20.9 million), an increase of 29.1% from RMB 117.3 million in Q1 2024, primarily due to the expansion of branded aesthetic centers [7]. - Total operating expenses decreased by 20.4% to RMB 189.3 million (US$ 26.1 million) from RMB 237.8 million in Q1 2024 [10]. Business Outlook - For Q2 2025, So-Young expects aesthetic treatment services revenues to be between RMB 120.0 million (US$ 16.5 million) and RMB 140.0 million (US$ 19.3 million), representing a 337.3% to 410.1% increase from the same period in 2024 [19].

Market Capitalization Overview - The market capitalizations of various companies are listed, with notable figures including 74.11 billion, 88.55 billion, and 76.47 billion [2] - Companies such as SON, VIPS, and TAL have market caps of 72.19 billion, 60.28 billion, and 55.72 billion respectively [2] Stock Performance - Stock price changes are highlighted, with SON showing a decrease of 0.95 (-1.99%) while VIPS increased by 0.15 (+0.85%) [2] - Other companies like TAL and Lufax also experienced minor fluctuations, with TAL decreasing by 0.04 (-0.49%) and Lufax increasing by 0.96 (+3.75%) [2] Additional Company Insights - Companies such as Huya and Yatsen have market caps of 8.06 billion and 3.27 billion respectively, with stock price changes of -0.03 (-0.77%) and 0.00 (0.00%) [2] - The performance of companies like New Oxygen and Huami Technology is also noted, with market caps of 83.07 million and 37.63 million, showing no change in stock price [3] Summary of Smaller Companies - Smaller companies like Tuniu and Cheetah Mobile have market caps of 1.08 billion and 1.17 billion respectively, with Tuniu experiencing a slight decrease of -0.01 (-1.20%) [3] - The market cap of Baosheng E-commerce is reported at 2.02 billion, with a stock price increase of 0.17 (+5.18%) [3]

Core Viewpoint - So-Young International Inc. is set to report its financial results for Q1 2025 on May 16, 2025, before U.S. markets open, highlighting its position as a leading aesthetic treatment platform in China [1][2]. Group 1: Financial Reporting - The financial results for the first quarter ended March 31, 2025, will be announced before U.S. markets open on May 16, 2025 [1]. - An earnings conference call is scheduled for May 16, 2025, at 7:30 AM U.S. Eastern Time, with dial-in details provided for international and local participants [2]. Group 2: Company Overview - So-Young International Inc. is recognized as the leading aesthetic treatment platform in China, connecting consumers with both online services and offline treatments [3]. - The company offers access to aesthetic treatments through its online platform and branded aesthetic centers, providing curated treatment information and facilitating online reservations [3]. - So-Young is positioned to grow along the medical aesthetic value chain due to its strong brand recognition, digital reach, affordable treatments, and efficient supply chain [3].

Market Capitalization Overview - The market capitalizations of various companies are listed, with TAL Education Group at 11.882 billion, Vipshop at 8.481 billion, and others showing significant values [2]. - Notable increases in market value include SouFun Technology with a rise of 9.49% and 6.96% for Lufax Holding [2]. Company Performance - TAL Education Group shows a slight decrease of 0.25% in its stock price, while Vipshop and SouFun Technology have increased by 6.38% and 7.51% respectively [2]. - Other companies like JD.com and iQIYI also show positive stock performance, with increases of 7.38% and 9.29% respectively [2]. Sector Analysis - The data indicates a mixed performance across the sector, with some companies experiencing growth while others face declines [2][3]. - Companies such as Huami and Mogujie show varied performance, with Huami experiencing a slight increase of 3.14% while Mogujie saw a decrease of 5.30% [3]. Investment Insights - The overall market sentiment appears to favor companies with strong growth metrics, as evidenced by the significant percentage increases in market value for several firms [2][3]. - The data suggests potential investment opportunities in companies that are showing consistent growth in their market capitalizations and stock prices [2].

Core Viewpoint - The company is undergoing a significant business transformation, shifting focus from an online medical beauty platform to a chain of physical clinics, while also extending upstream in the industry chain [2][3]. Financial Performance - In 2024, the company's total revenue is projected to be 1.47 billion yuan, a year-on-year decrease of 2.1%, with core business revenue from information and appointment services dropping 19.3% to 930 million yuan [2]. - The chain business, however, has shown remarkable growth, achieving revenue of 170 million yuan, a year-on-year increase of over 1200% [2]. Business Strategy - The CEO indicated that the transformation was necessary due to the increasing competition from larger platforms like Meituan and Alibaba, which have a competitive edge in online traffic [2]. - The company aims to establish itself as the largest offline brand in the domestic medical beauty industry, with plans to expand from 25 to 50 clinics by the end of the year and ultimately to 1000 clinics in the long term [3]. Market Positioning - The new clinics, named "Xinyang Youth Clinics," focus on "light medical beauty" services, offering high-quality, low-cost treatments without the need for surgical procedures [8][10]. - The clinics operate on a model that avoids traditional practices like membership cards and prepayments, aiming to maximize profit margins through self-operated services [10]. Competitive Landscape - The company faces challenges from existing medical beauty institutions, which view its entry into the physical clinic space as a threat to their business [5][6]. - Despite some backlash, many institutions have chosen to continue their partnerships with the company, indicating a recognition of the potential for market expansion [6]. Future Outlook - The company has invested significantly in upstream operations, including acquiring stakes in medical device companies and establishing its own production facilities for beauty products [8][9]. - The CEO believes that the medical beauty market in China is still growing, with the potential for the company to capture a larger market share despite current financial pressures [12][14].

Financial Performance - Revenues from consolidated affiliated entities accounted for 78.9%, 80.4%, and 80.0% of total revenues for the years ended December 31, 2022, 2023, and 2024, respectively [28]. - The total revenues for the year ended December 31, 2024, amounted to RMB 1,466.7 million, a slight decrease from RMB 1,498.0 million in 2023 [52]. - The net loss attributable to So-Young International Inc. for the year ended December 31, 2024, was RMB 589.5 million, compared to a net income of RMB 21.3 million in 2023 [52]. - The total operating expenses for the year ended December 31, 2024, were RMB 1,523.6 million, an increase from RMB 1,014.7 million in 2023 [52]. - Total revenues increased by 19.1% from RMB 1,257.9 million in 2022 to RMB 1,498.0 million in 2023, but decreased by 2.1% to RMB 1,466.7 million (US$200.9 million) in 2024 [69]. - Gross profit rose by 10.3% from RMB 864.6 million in 2022 to RMB 953.7 million in 2023, but fell by 5.7% to RMB 899.1 million (US$123.2 million) in 2024 [69]. - Gross margin decreased from 68.7% in 2022 to 63.7% in 2023, and further decreased to 61.3% in 2024 [69]. Cash Flow and Liquidity - Cash and cash equivalents increased to RMB 587,749,000 in 2024 from RMB 426,119,000 in 2023, reflecting a growth of about 37.9% [55][56]. - Net cash provided by operating activities was RMB (25,633,000) for the year ended December 31, 2024, compared to RMB (25,633,000) in 2023, indicating no change in operational cash flow [58]. - The company reported a net cash increase of RMB 213,229,000 in 2024, up from RMB 432,740,000 at the beginning of the year [58]. - The total amount due from Group companies was RMB 1,894,656,000 in 2024, a decrease from RMB 2,512,057,000 in 2023, reflecting a reduction of approximately 24.5% [55][56]. - The company reported a net cash used in investing activities of RMB 202,611 thousand for 2023, compared to a net cash provided of RMB 572,212 thousand in 2022, highlighting a shift in investment strategy [59]. - The company’s cash flow from operating activities improved significantly, with a net cash provided of RMB 22,501 thousand in 2023 compared to a net cash used of RMB 112,873 thousand in 2022, showing operational efficiency [59]. Regulatory Environment - The PCAOB was unable to inspect registered public accounting firms in mainland China and Hong Kong, which could affect the trading of the company's shares under the Holding Foreign Companies Accountable Act [38]. - The company may face significant risks related to regulatory approvals and oversight in China, which could adversely affect operations and share value [36]. - Regulatory compliance is critical, as failure to obtain necessary licenses and permits could disrupt operations and delay expansion plans [90]. - The PRC tax authorities may challenge the contractual arrangements, leading to additional tax liabilities that could negatively impact the company's financial condition [187]. - The Foreign Investment Law introduces uncertainties regarding the company's corporate structure and operations, which could affect compliance and governance [190]. - The PRC government's oversight could materially affect operations and the value of the company's ADSs [206]. Operational Risks - The company faces potential legal claims and regulatory investigations related to the medical information and services offered on its platform [70]. - The company faces risks related to the acquisition of Wuhan Miracle, including challenges in integration and potential unanticipated expenses [91]. - The integration of Wuhan Miracle may result in operational challenges and could impact the anticipated benefits of the acquisition [91]. - The company must navigate a complex regulatory environment for medical equipment, which poses challenges for product acceptance and market competition [92]. - The company faces risks related to geopolitical tensions, particularly between the United States and China, which could negatively impact its business operations [161]. Market and Competitive Landscape - The online medical aesthetic service market is highly competitive, with risks of losing market share if the company cannot compete effectively [121]. - Average fee rates for medical aesthetic treatments in China are expected to decline, which could adversely affect the company's profitability and financial condition [123]. - Negative market perception of the medical aesthetic industry could lead to reduced consumer confidence and demand for services [98]. - The company’s expansion strategies may be affected by competition, regulatory challenges, and the need to adapt to local market conditions [82]. Financial Structure and Taxation - Under the PRC Enterprise Income Tax Law, dividends paid by foreign-invested enterprises to foreign non-resident investors are subject to a 10% withholding tax [41]. - The hypothetical tax scenario indicates that a 25% tax on earnings and a 10% withholding tax could reduce net distributions to shareholders to 67.5% of pre-tax earnings [42]. - The classification as a resident enterprise in mainland China could lead to a 25% PRC enterprise income tax on global income for the company and its non-resident shareholders [224]. - If deemed a resident enterprise, the company may need to withhold a 10% tax on dividends paid to non-resident shareholders, including ADS holders [227]. - The company faces uncertainties regarding the indirect transfer of equity interests and potential re-characterization of such transfers as direct transfers subject to PRC enterprise income tax [228]. Corporate Governance and Management - The company relies on maintaining high-quality content to attract and retain users, which is essential for user engagement and competitive positioning [93]. - The company relies on key employees for its success, and failure to retain them could have a material adverse effect on its business [149]. - The company has implemented strict procedures to verify the qualifications of medical service providers, but cannot guarantee all providers are fully licensed [73]. - The company has raised substantial financing since its inception to support growth and may require additional capital for brand awareness, new services, geographic expansion, and acquisitions [156]. Cash Management and Financial Reporting - The company’s internal control over financial reporting was deemed effective as of December 31, 2024, by management and its independent registered public accounting firm [171]. - The company maintains limited business insurance coverage, which may expose it to substantial costs and resource diversion if uninsured risks materialize [155]. - The company recorded share-based compensation expenses of RMB 43.3 million, RMB 36.3 million, and RMB 32.7 million (US$4.5 million) for the years 2022, 2023, and 2024, respectively [169].

深圳商报在报道《新氧"缺氧"！亏损5.87亿元创4年新高，核心业务下降明显》中表示，这是新氧 集团近4年来亏损最大的一年，2021年和2022年其连亏两年，2023年扭亏为盈，直至2024年再次陷入 亏损境地。新氧预计2025年第一季度营收为2.8亿元(约3840万美元)到3亿元(4110万美元)，较上年同期 下降5.7%到12%。 财中社报道《新氧转型阵痛持续：5.4亿元巨额商誉减值加剧亏损》显示，2024年，新氧核心业务 ——信息及预约服务收入同比锐减19.3%至9.295亿元，反映医美机构付费意愿下降。化妆品销售带动 医疗产品收入增长10.3%至3.68亿元，品牌美容中心延伸服务拉动治疗收入增至1.69亿元，但未能抵消 主业萎缩。第四季度医美设备订单减少致医疗产品收入再降15.2%。截至2024年底，新氧现金储备同 比减少6.6%至12.53亿元。公司预计2025年第一季度营收继续下滑5.7%-12%。 中国经济网北京4月9日讯 医美服务在线平台新氧(Nasdaq:SY)近日发布2024年全年财报。财报显 示，公司2024年营收14.67亿(约2亿美元)，较上年同期下降2.1%；净亏损5.87亿元(约8 ...